ZIM Laboratories Limited (BOM:541400)
118.15
-2.40 (-1.99%)
At close: Jul 7, 2026
ZIM Laboratories Revenue
In the fiscal year ending March 31, 2026, ZIM Laboratories had annual revenue of 3.74B INR, down -1.22%. ZIM Laboratories had revenue of 1.05B in the quarter ending March 31, 2026, a decrease of -3.18%.
Revenue
3.74B
Revenue Growth
-1.22%
P/S Ratio
1.69
Revenue / Employee
5.92M
Employees
632
Market Cap
6.33B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.74B | -46.31M | -1.22% |
| Mar 31, 2025 | 3.79B | 115.14M | 3.13% |
| Mar 31, 2024 | 3.68B | -310.92M | -7.80% |
| Mar 31, 2023 | 3.99B | 651.00M | 19.52% |
| Mar 31, 2022 | 3.34B | 261.64M | 8.51% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anuh Pharma | 7.72B |
| Sudarshan Pharma Industries | 7.03B |
| Kopran | 6.81B |
| Wanbury | 6.50B |
| Fermenta Biotech | 5.25B |
| Hexagon Nutrition | 3.83B |
| Bharat Parenterals | 3.45B |
| Albert David | 3.34B |
ZIM Laboratories News
- 7 months ago - Why ZIM Laboratories has received CDSCO approval for its new Naproxen + Esomeprazole capsules - Business Upturn
- 1 year ago - ZIM Laboratories secures marketing authorization in Australia for urology drug combination - Business Upturn
- 1 year ago - ZIM Laboratories shares in focus as company gets first marketing approval in Australia - Business Upturn